

Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9372640-00007	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier							
Trade name	:	Betamethasone / Clotrimazole Ointment Formulation					
1.2 Relevant identified uses of	1.2 Relevant identified uses of the substance or mixture and uses advised against						
Use of the Sub- stance/Mixture	:	Pharmaceutical					
Recommended restrictions on use	:	Not applicable					
1.3 Details of the supplier of th	e saf	ety data sheet					
Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain					
Telephone	:	+44 1 670 59 32 05					
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com					

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Reproductive toxicity, Category 1BHSpecific target organ toxicity - repeatedHexposure, Category 1IdLong-term (chronic) aquatic hazard, Cat-Hegory 1egory 1

H360D: May damage the unborn child. H372: Causes damage to organs through prolonged or repeated exposure. H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		SDS Number: 9372640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Hazard pictograms		:		¥_2
Signa	l word	:	Danger	•
Hazar	d statements	:	H372 C	lay damage the unborn child. Causes damage to organs through prolonged or epeated exposure.
			H410 V	ery toxic to aquatic life with long lasting effects.
Preca	utionary statements	:	Prevention:	
	-		P264 V P273 A P280 V	Dbtain special instructions before use. Vash skin thoroughly after handling. woid release to the environment. Vear protective gloves/ protective clothing/ eye protection/ face protection.
			Response: P308 + P313	IF exposed or concerned: Get medical advice/
			•.	ttention. Collect spillage.

Hazardous components which must be listed on the label: betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
clotrimazole	23593-75-1 245-764-8	Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repr. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Ad- renal gland) Aquatic Acute 1; H400 Aquatic Chronic 1;	>= 1 - < 2.5

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9372640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	_
betan	nethasone	378-44-9 206-825-4	H410M-Factor (Acute aquatic toxicity): 10M-Factor (Chronic aquatic toxicity): 10Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Ad- renal gland) Aquatic Chronic 1; H410M-Factor (Chronic aquatic toxicity): 1,000M-Factor (Chronic aquatic toxicity): 1,000specific concentra- 	
			>= 0.01 % Repr. 1B; H360D >= 0.01 % STOT RE 1; H372 >= 0.01 % Repr. 1B; H360D	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures					
General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.			
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).			
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.			



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9372640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021		
In case of skin contact		of water. Remove contar Get medical att Wash clothing			
In case of eye contact			Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.		
lf swa	allowed	Get medical att	O NOT induce vomiting. ention. oroughly with water.		
4.2 Most i	mportant symptoms	and effects, both act	ute and delayed		
Risks		: May damage th	ne unborn child. e to organs through prolonged or repeated		
4.3 Indica	tion of any immediat	e medical attention a	ind special treatment needed		
Treat	ment	: Treat symptom	atically and supportively.		

SECTION 5: Firefighting measures

5.1 Extinguishing media Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising from	n the	e substance or mixture
Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	• :	Carbon oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	t :	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Nu 9372640		Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
0.0	00.04.2024	5572040	00001	
		Rem so.		y to cool unopened containers. naged containers from fire area if it is safe to do
SECTION	6: Accidental rele	ease meas	ures	
6.1 Persor	nal precautions. pro	tective equi	pment and	d emergency procedures
	nal precautions	-	-	
1 0100		ons : Use personal protective equipment. Follow safe handling advice (see section 7) and persona tective equipment recommendations (see section 8).		
6.2 Enviro	nmental precaution	S		
Enviro	onmental precautions	: Avoi	d release to	o the environment.
				leakage or spillage if safe to do so.
				ose of contaminated wash water.
			•	s rivers or watercourses, inform the Environ- emergency telephone number 0800 807060).
6.3 Metho	ds and material for o	ontainmen	t and clear	ning up
Metho	ods for cleaning up			cuum up spillage and collect in suitable con-
			r for dispos	
				al regulations may apply to releases and dis-
				aterial, as well as those materials and items e cleanup of releases. You will need to deter-
		•		ulations are applicable.
			minoritogi	

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	-	
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaus ventilation.	st
Advice on safe handling	: Do not get on skin or clothing.	
9	Do not breathe dust, fume, gas, mist, vapours or spray.	
	Do not swallow.	
	Avoid contact with eyes.	
	Wash skin thoroughly after handling.	
	Handle in accordance with good industrial hygiene and saf	fetv
	practice, based on the results of the workplace exposure a	
		12-
	sessment	
	Keep container tightly closed.	
	·····	

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9372640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
Hygiene measures		 Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 		
7.2 Condit	ions for safe storage,	including any in	compatibilities	
	rements for storage and containers		perly labelled containers. Store locked up. Keep d. Store in accordance with the particular national	
Advic	e on common storage	Strong oxidi	e substances and mixtures	
•	ic end use(s) fic use(s)	: No data ava	ilable	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
clotrimazole 23593-75-1		TWA	0.2 mg/m3 (OEB 2)	Internal
betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	nation: Skin		
		Wipe limit	10 µg/100 cm²	Internal

Predicted No Effect Concentration (PNEC):

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		OS Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021		
closed system, packout head with inflatable seal from stationary container, ventilated enclo etc.). All engineering controls should be implemented by facility design and operated in accordan with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.						
Pers	sonal protective equip	nent				
Eye	/face protection	:	If the work enviro mists or aerosols Wear a faceshiel	ses with side shields or goggles. nment or activity involves dusty conditions, , wear the appropriate goggles. d or other full face protection if there is a et contact to the face with dusts, mists, or		
Har	d protection					
Ν	laterial	:	Chemical-resistar	nt gloves		
-	Remarks and body protection	:	being performed suits) to avoid exp	aboratory coat. arments should be used based upon the task (e.g., sleevelets, apron, gauntlets, disposable bosed skin surfaces. legowning techniques to remove potentially		
Res	piratory protection	:	If adequate local sure assessment ommended guide Equipment should	exhaust ventilation is not available or expo- demonstrates exposures outside the rec- lines, use respiratory protection. d conform to BS EN 14387		
F	ilter type	:	Combined particu	lates and organic vapour type (A-P)		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance	:	Viscous semi-solid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	Not classified as a flammability hazard

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Ver 5.0	sion	Revision Date: 06.04.2024		S Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
		explosion limit / Upper ability limit	:	No data available	
		explosion limit / Lower ability limit	:	No data available	9
	Vapou	rpressure	:	Not applicable	
	Relativ	e vapour density	:	Not applicable	
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
	Partitio octano	ter solubility n coefficient: n-	:	No data available Not applicable No data available	
	-	position temperature	:	No data available	
	Viscos Visc	ity cosity, kinematic	:	No data available	9
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2		nformation		No data available	
		ability (liquids)	•		;
	Particle	e size	:	Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity							
Not classified as a reactivity hazard.							
10.2 Chemical stability							
Stable under normal cor	ditions.						
10.3 Possibility of hazardo	us reactio	ns					
Hazardous reactions	:	Can react with strong oxidizing agents.					
10.4 Conditions to avoid							
Conditions to avoid	:	None known.					



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		9S Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
10.5 Incoi	npatible materials			
Mater	rials to avoid	:	Oxidizing agents	6
	rdous decomposition azardous decompositior	-		
	11: Toxicological i	•		
11.1 Infor	mation on toxicologic	al ef	fects	
	nation on likely routes o		Skin contact Ingestion Eye contact	
	e toxicity			
	lassified based on avail	lable	information.	
Prod Acute	uct: oral toxicity		Acute toxicity est	imate: > 2,000 mg/kg
Acute		•	Method: Calculat	
Acute	e dermal toxicity	:	Acute toxicity est Method: Calculat	timate: > 2,000 mg/kg tion method
Com	oonents:			
	mazole:			
Acute	oral toxicity	:	LD50 (Rat): 708	
			LD50 (Mouse): 7	61 mg/kg
			LD50 (Rabbit): >	1,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 0.7	
			Exposure time: 4 Test atmosphere	· h :: dust/mist
Acute	e dermal toxicity	:	LD50 (Mouse): 9	
 heter	nethasone:			
	e oral toxicity	:	LD50 (Rat): > 5,0	000 mg/kg
			LD50 (Mouse): >	4,500 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): 0.4 r Exposure time: 4	

Skin corrosion/irritation

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Versior 5.0	n Revision Date: 06.04.2024	SDS Number: 9372640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
C	omponents:		
	otrimazole: Decies	: Rabbit	
	esult	: No skin irrita	tion
	etamethasone: Decies	: Rabbit	
	esult	: Mild skin irrit	ation
Se	erious eye damage/eye	irritation	
	ot classified based on av		
<u>C</u>	omponents:		
	otrimazole:		
	pecies	: Rabbit	
	esult	: Mild eye irrit	ation
be	etamethasone:		
Sp	pecies	: Rabbit	
Re	esult	: No eye irrita	ion
Re	espiratory or skin sens	itisation	
SI	kin sensitisation		
No	ot classified based on av	ailable information.	
Re	espiratory sensitisatior	ı	
No	ot classified based on av	ailable information.	
<u>C</u>	omponents:		
be	etamethasone:		
	posure routes	: Dermal	
	pecies esult	: Guinea pig : Weak sensit	zor
	esuit	. Weak sensit	
G	erm cell mutagenicity		
No	ot classified based on av	ailable information.	
<u>C</u>	omponents:		
cl	otrimazole:		
G	enotoxicity in vitro	: Test Type: E Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: C Result: nega	chromosome aberration test in vitro tive
		10 /	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		S Number: 2640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
			Test Type: in vitro Result: negative	micronucleus test
Genc	otoxicity in vivo		Test Type: Mamm cytogenetic assay Species: Rat Application Route Result: negative	
			Test Type: Mamm tion test (in vivo) Species: Hamster Result: negative	alian spermatogonial chromosome aberra-
Germ sessi	n cell mutagenicity- As- ment		Weight of evidenc cell mutagen.	e does not support classification as a germ
betai	methasone:			
	otoxicity in vitro		Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
			Test Type: In vitro Result: negative	mammalian cell gene mutation test
			Test Type: Chrom Result: positive	osome aberration test in vitro
Genc	otoxicity in vivo		Test Type: Mamm cytogenetic assay Species: Mouse Application Route Result: equivocal	
Germ sessi	n cell mutagenicity- As- ment		Weight of evidenc cell mutagen.	e does not support classification as a germ
	inogenicity classified based on availa	able ii	nformation.	
<u>Com</u>	ponents:			
clotr	imazole:			
Spec Appli	ies cation Route sure time	:	Rat Oral 78 weeks negative	

Reproductive toxicity

May damage the unborn child.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



ersion .0	Revision Date: 06.04.2024	SDS Number: 9372640-0000	
Com	ponents:		
clotri	imazole:		
Effec	ts on fertility	Species: F Application Fertility: L	: Fertility/early embryonic development Rat n Route: Oral OAEL: 50 mg/kg body weight rects on fertility
Effec ment	ts on foetal develop-	Species: F Application Developm Result: En Test Type Species: F Application	n Route: Oral ental Toxicity: LOAEL: 100 mg/kg body weight nbryo-foetal toxicity, No teratogenic effects : Embryo-foetal development
		Result: En	nbryo-foetal toxicity, No teratogenic effects : Embryo-foetal development
		Species: M Application Developm	
		Species: F Application Developm	: Embryo-foetal development Rabbit n Route: Oral ental Toxicity: NOAEL: 180 mg/kg body weight o effects on foetal development
Repro sessr	oductive toxicity - As- nent	fertility, ba	dence of adverse effects on sexual function and sed on animal experiments., Some evidence of ffects on development, based on animal experi-
betar	nethasone:		
Effec ment	ts on foetal develop-	Developm	Rabbit n Route: Intramuscular ental Toxicity: LOAEL: 0.05 mg/kg body weight totoxicity, Malformations were observed.
		Developm	Rat n Route: Subcutaneous ental Toxicity: LOAEL: 0.42 mg/kg body weight alformations were observed.
		Species: M Application	/louse n Route: Intramuscular
		11	2/21

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Malformations were observed. Reproductive toxicity - As- sessment Clear evidence of adverse effects on development, based animal experiments. STOT - single exposure Not classified based on available information. STOT - repeated exposure Causes damage to organs through prolonged or repeated exposure. Components: clotrimazole: Target Organs Liver, Kidney, Adrenal gland Assessment May cause damage to organs through prolonged or repeate exposure. betamethasone: Target Organs Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment Target Organs Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment Causes damage to organs through prolonged or repeated exposure. Betamethasone: Target Organs Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity E Components: clotrimazole: Debbit	on
sessment animal experiments. STOT - single exposure Not classified based on available information. STOT - repeated exposure Causes damage to organs through prolonged or repeated exposure. Components: clotrimazole: Target Organs : Liver, Kidney, Adrenal gland Assessment : May cause damage to organs through prolonged or repeated exposure. betamethasone: Target Organs : Private Organs : Assessment : Assessment : Private Organs : Private Organs : Private Organs : Private Organs : Adrenal gland : Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Components: : clotrimazole: :	l on
Not classified based on available information. STOT - repeated exposure Causes damage to organs through prolonged or repeated exposure. Components: clotrimazole: Target Organs : Liver, Kidney, Adrenal gland Assessment : betamethasone: Target Organs : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. betamethasone: Target Organs : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity Components: clotrimazole:	
Causes damage to organs through prolonged or repeated exposure. Components: clotrimazole: Target Organs : Liver, Kidney, Adrenal gland Assessment : May cause damage to organs through prolonged or repeated exposure. betamethasone: Target Organs : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity Components: clotrimazole:	
Components: clotrimazole: Target Organs : Liver, Kidney, Adrenal gland Assessment : May cause damage to organs through prolonged or repeated exposure. betamethasone: . Target Organs : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Components: clotrimazole: : :	
Target Organs : Liver, Kidney, Adrenal gland Assessment : May cause damage to organs through prolonged or repeated exposure. betamethasone: : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Components: clotrimazole: : :	
Assessment : May cause damage to organs through prolonged or repeated exposure. betamethasone: : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Components: clotrimazole: : Pituitary gland, Immune system, muscle, thymus gland, B Adrenal gland	
Target Organs : Pituitary gland, Immune system, muscle, thymus gland, B Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity : Components: clotrimazole: : Cause damage to organs	ited
Adrenal gland Assessment : Causes damage to organs through prolonged or repeated exposure. Repeated dose toxicity <u>Components:</u> clotrimazole:	
exposure. Repeated dose toxicity <u>Components:</u> clotrimazole:	lood,
Components: clotrimazole:	1
clotrimazole:	
Chaption . Dath	
Species : Rabbit LOAEL : 5 - 40 mg/kg	
LOAEL : 5 - 40 mg/kg Application Route : Skin contact	
Exposure time : 3 Weeks	
Target Organs : Skin	
Symptoms : Oedema, Fissuring, Necrosis, Redness	
Species : Rat	
LOAEL : 10 mg/kg	
Application Route : Oral	
Exposure time : 18 Months Target Organs : Liver, Kidney, Adrenal gland	
Species : Dog	
LOAEL : 25 mg/kg Application Route : Oral	
Application Route:OralExposure time:6 - 12 Months	
Target Organs : Adrenal gland	
Symptoms : Salivation, Lachrymation, Vomiting	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Numbe 9372640-000	
Specie LOAEL Applica Exposu Target Specie LOAEL Applica	ation Route ure time Organs s	: Rabbit : 0.05 % : Skin cont : 10 - 30 d : Pituitary : Rat : 0.05 % : Skin cont : 8 Weeks	ntact d ⁄ gland, Immune system, muscle ntact
Exposu Target Specie LOAEL Applica Exposu	s ation Route ure time Organs s	 thymus g Mouse 0.1 % Skin cont 8 Weeks thymus g Dog 0.05 mg, Oral 28 d Blood, th 	ntact s gland
Not cla Experi Compo clotrin Skin co Ingestio	ontact on ethasone:	: Symptom : Symptom	on. ms: Rash, Itching, Blistering, Oedema, Redness ms: Abdominal pain, Nausea, Vomiting, Diarrhoea Organs: Adrenal gland
Skin co		: Symptom	ms: Redness, pruritis, Irritation

12.1 Toxicity

Components:

clotrimazole:

Toxicity to fish

 LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l Exposure time: 96 h Method: OECD Test Guideline 203



Version 5.0	Revision Date: 06.04.2024		0S Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
	tity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): 0.02 mg/l } h
Toxic plant	sity to algae/aquatic s	:	EC50 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 0.268 mg/l ? h
			NOEC (Desmodesmus subspicatus (green algae)): 0.01 Exposure time: 72 h	
M-Fa icity)	ctor (Acute aquatic tox-	:	10	
Toxic	to microorganisms	:	EC50 : > 10,000 r Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
Toxic icity)	sity to fish (Chronic tox-	:	NOEC: 0.025 mg/ Exposure time: 32 Species: Oncorhy Method: OECD Te	2 d nchus mykiss (rainbow trout)
	tity to daphnia and other tic invertebrates (Chron- cicity)		Exposure time: 21	magna (Water flea)
M-Fa toxici	ictor (Chronic aquatic ty)	:	10	
beta	methasone:			
	tity to daphnia and other tic invertebrates	:	EC50 (Americamy Exposure time: 96	
Toxic plant	sity to algae/aquatic s	:	mg/l Exposure time: 72 Method: OECD Te	
			mg/l Exposure time: 72 Method: OECD Te	
Toxic icity)	to fish (Chronic tox-	:	NOEC: 0.052 mg/ Exposure time: 32 Species: Pimepha Method: OECD Te	2 d ales promelas (fathead minnow)
II			NOEC: 0.07 µg/l	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		OS Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
			Exposure time: 2 Species: Oryzias Method: OECD T	latipes (Japanese medaka)
	y to daphnia and other c invertebrates (Chron- city)		NOEC: 8 mg/l Exposure time: 2 Species: Daphnia Method: OECD T	magna (Water flea)
M-Fac toxicity	tor (Chronic aquatic /)	:	1,000	
12.2 Persis	stence and degradabil	ity		
<u>Comp</u>	onents:			
	nazole: ty in water	:	Hydrolysis: 50 %(242 d)
12.3 Bioac	cumulative potential			
<u>Comp</u>	onents:			
	ethasone: on coefficient: n- ol/water	:	log Pow: 2.11	
12.4 Mobil i No dat	ity in soil ta available			
12.5 Resul	ts of PBT and vPvB as	sse	ssment	
<u>Produ</u> Asses		:	to be either persis	ixture contains no components considered stent, bioaccumulative and toxic (PBT), or ad very bioaccumulative (vPvB) at levels of
12.6 Other adverse effects				
Produ Endoc tial	<u>ct:</u> rine disrupting poten-	:	ered to have end	ixture does not contain components consid- ocrine disrupting properties for environment REACH Article 57(f).

SECTION 13: Disposal considerations

:

13.1 Waste treatment methods

Product

Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9372640-00007	Date of first issue: 27.08.2021
Conta	minated packaging	Waste codes sh discussion with Do not dispose of Empty container dling site for rec	specific, but application specific. ould be assigned by the user, preferably in the waste disposal authorities. of waste into sewer. rs should be taken to an approved waste han- ycling or disposal. specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number			
ADN	:	UN 3077	
ADR	:	UN 3077	
RID	:	UN 3077	
IMDG	:	UN 3077	
ΙΑΤΑ	:	UN 3077	
14.2 UN proper shipping name			
ADN	:	ENVIRONMENTALLY H. N.O.S. (betamethasone, clotrima	AZARDOUS SUBSTANCE, SOLID, azole)
ADR	:	ENVIRONMENTALLY H. N.O.S. (betamethasone, clotrima	AZARDOUS SUBSTANCE, SOLID, azole)
RID	:	ENVIRONMENTALLY H. N.O.S. (betamethasone, clotrima	AZARDOUS SUBSTANCE, SOLID, azole)
IMDG	:	ENVIRONMENTALLY H. N.O.S. (betamethasone, clotrima	AZARDOUS SUBSTANCE, SOLID, azole)
ΙΑΤΑ	:	Environmentally hazardo (betamethasone, clotrima	ous substance, solid, n.o.s. azole)
14.3 Transport hazard class(es)			
		Class Su	ubsidiary risks
ADN	:	9	
ADR	:	9	
RID	:	9	
IMDG	:	9	
ΙΑΤΑ	:	9	
14.4 Packing group			
ADN			

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Versio 5.0		Revision Date: 06.04.2024		S Number: 72640-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
C H		group ation Code Identification Number		III M7 90 9	
P C H La	lazard abels	group ation Code Identification Number restriction code	: : : : : : : : : : : : : : : : : : : :	III M7 90 9 (-)	
P C H		group ation Code Identification Number	: : :	III M7 90 9	
P La	MDG Packing abels EmS Co		: :	III 9 F-A, S-F	
P ai P P	ircraft)	instruction (cargo instruction (LQ)	:	956 Y956 III Miscellaneous	
l / P gr P P	ATA (P Packing er aircr	instruction (LQ)	:	956 Y956 III Miscellaneous	
		mental hazards			
E		mentally hazardous	:	yes	
	DR Invironi	mentally hazardous	:	yes	
	RID Environi	mentally hazardous	:	yes	
	MDG 1arine p	pollutant	:	yes	
		assenger) mentally hazardous	:	yes	
	ATA (C Invironi	a rgo) mentally hazardous	:	yes	



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9372640-00007	Date of first issue: 27.08.2021

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (UK REACH Candidate list of su concern (SVHC) for Authorisati	bstances of very high	:	Not applicable Not applicable	
The Persistent Organic Pollutar Regulation (EU) 2019/1021 as ain)	nts Regulations (retained	:	Not applicable	
Regulation (EC) No 1005/2009 plete the ozone layer	on substances that de-	:	Not applicable	
UK REACH List of substances (Annex XIV)	subject to authorisation	:	Not applicable	
GB Export and import of hazard Informed Consent (PIC) Regula		:	Not applicable	
Control of Major Accident Haza		OMA	λH)	
-	-		Quantity 1	Quantity 2
E1	ENVIRONMENTAL HAZARDS		100 t	200 t

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.



Betamethasone / Clotrimazole Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9372640-0000	Date of last issue: 30.09.2023 7 Date of first issue: 27.08.2021		
SECTION	N 16: Other informa	ation			
Other	Other information :		Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.		
Full t	ext of H-Statements				
H302 H311 H319 H330 H360 H361	D	: Causes se : Fatal if inh : May dama	ntact with skin. rious eye irritation.		
H372		: Causes da exposure.	unborn child. Causes damage to organs through prolonged or repeated		
H373 H400 H410		exposure in exposu	 May cause damage to organs through prolonged or repeated exposure if swallowed. Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects. 		
Full t	ext of other abbrevia	-			
Aqua		: Long-term : Eye irritatio : Reproduct	(acute) aquatic hazard (chronic) aquatic hazard on		
Wate Road ing of tion (of the Europ	rways; ADR - Agree ; AIIC - Australian Inv f Materials; bw - Body EC) No 1272/2008; C e German Institute for bean Chemicals Agen	ment concerning entory of Industria weight; CLP - Cla MR - Carcinogen, Standardisation; cy; EC-Number -	nternational Carriage of Dangerous Goods by Inland he International Carriage of Dangerous Goods by I Chemicals; ASTM - American Society for the Test- assification Labelling Packaging Regulation; Regula- Mutagen or Reproductive Toxicant; DIN - Standard DSL - Domestic Substances List (Canada); ECHA - European Community number; ECx - Concentration		

of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9372640-00007	Date of first issue: 27.08.2021

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Ager cy, http://echa.europa.eu/	
Classification of the mixture:		Classification procedure:
D 4D	10000	

Repr. 1B	H360D	Calculation method
STOT RE 1	H372	Calculation method
Aquatic Chronic 1	H410	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN